ABOUT US OUR SCIENCE OUR PRODUCT NEWS CONTACT News OCT 18, 2021 Avelas Makes Senior Appointments and Provides Update on Pegloprastide Phase III Clinical Program READ MORE APR 29, 2021 Avelas Biosciences Presents Phase 2, Period 2 Data in Virtual Poster Session at the 22nd Annual Meeting of The American Society of Breast Surgeons READ MORE DEC 14, 2020 Avelas Receives FDA Breakthrough Therapy Designation for Pegloprastide (AVB-620) for Use During Breast Cancer Surgery READ MORE AUG 04, 2020 Avelas Announces Top-Line Data Showing Pegloprastide (AVB-620) Can Significantly Improve Cancer Detection in Real-Time During Breast Cancer Surgery READ MORE FEB 26, 2020 Avelas Biosciences Voted Innovator of the Year at Field Service Medical 2020 READ MORE NOV 22, 2019 Avelas Welcomes Susan Stimson to its Board of Directors READ MORE JUN 17, 2019 Avelas Biosciences Selected as a 2019 Showcase Company by MedTech Innovator READ MORE MAR 04, 2019 Avelas Biosciences Grows Management Team READ MORE DEC 04, 2018 Avelas Biosciences Presents Phase II, Period 1 Data in Poster Session at San Antonio Breast Cancer Symposium READ MORE Next Page » HOME ABOUT US OUR SCIENCE OUR PRODUCT NEWS CONTACT Copyright © Avelas Biosciences | Website by AshWebStudio